市場調査レポート
商品コード
1335921

網膜生物製剤の世界市場規模・シェア・産業動向分析レポート:適応症別、薬剤クラス別、流通チャネル別、地域別展望・予測、2023年~2030年

Global Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

出版日: | 発行: KBV Research | ページ情報: 英文 229 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
網膜生物製剤の世界市場規模・シェア・産業動向分析レポート:適応症別、薬剤クラス別、流通チャネル別、地域別展望・予測、2023年~2030年
出版日: 2023年07月31日
発行: KBV Research
ページ情報: 英文 229 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

網膜生物製剤市場規模は2030年までに207億米ドルに達すると予測され、予測期間中のCAGRは5.4%の市場成長率で上昇します。

しかし、医薬品の承認には、多くの費用のかかる規制当局の承認や調査段階が必要です。医薬品の承認プロセスには、約4段階の臨床試験を含む、規制当局の審査が数段階含まれます。臨床試験段階には多額の投資が必要なため、失敗した研究のコストは高いです。例えば、フォーブス誌の記事によると、ある医薬品メーカーは、上市されるまでに1つの治療法に約3億5,000万米ドルを投資しています。待ち時間が長いと、こうした生産者にもコストがかかり、市場拡大の妨げになります。さらに、COVID-19の大流行によって、ヘルスケア業界のワークフローは世界的に影響を受けた。ヘルスケア・セクターのいくつかの地域や他のいくつかの産業が、病気のために一時的に閉鎖されました。COVID-19主導の世界の景気減速は、2020年の市場の落ち込みを引き起こしました。パンデミックはまた、製薬、ヘルスケア、産業部門を含むいくつかのエンドユーザー業界のサプライチェーンの低下を引き起こしました。このため市場が限定され、革新的な医薬品の発売にも影響が出ました。

適応症の展望

適応症に基づき、市場は黄斑変性症、糖尿病網膜症、その他に分類されます。黄斑変性症セグメントは、2022年の市場で最も高い収益シェアを獲得しました。網膜生物製剤は、網膜の炎症を抑え、異常な血管の形成を抑制することで、黄斑変性症患者の視力を維持し、さらなる視力低下を食い止めることができます。生物学的製剤を早期に効果的に使用することで、視力が安定したり、改善したりすることもあります。一部の網膜生物学的製剤は徐放性製剤であるため、注射や治療の頻度を減らすことができます。

薬剤クラス別展望

薬剤クラス別では、市場はVEGF-A拮抗薬とその他に区分されます。その他セグメントは2022年の市場で大きな収益シェアを記録しました。その他のセグメントには、主にTNF-αから開発された生物製剤が含まれます。炎症性サイトカインである腫瘍壊死因子α(TNF-α)は、マクロファージやT細胞によって生成されます。炎症とアポトーシスの両者において重要です。TNF-αは、眼における炎症性疾患、浮腫性疾患、新生血管疾患、神経変性疾患の発症に関与していると考えられています。

流通チャネルの展望

流通チャネルに基づき、市場は病院薬局、オンライン薬局、小売薬局に分けられます。オンライン薬局セグメントは、2022年の市場でかなりの成長率を確保しました。このセグメントの成長に影響を与える主な要因の1つは、様々な眼疾患の治療のために眼科クリニックを訪れる患者数の増加です。先進国でも発展途上国でも、インターネットを利用する人が増えており、患者はオンラインで医薬品を購入することを選ぶようになっています。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米地域は、2022年の市場において最大の収益シェアを記録しました。Bayer AGやNovartis AGをはじめとする数多くの大手企業の存在や、網膜生物製剤の生産における新興国市場の開拓が、市場拡大の原動力となっています。さらに、網膜生物学的製剤へのアクセスが容易であること、早期発見・早期治療の重要性に対する社会的認知が高まっていることも、この地域の市場拡大を後押しする主な要因となっています。さらに、病院、診療所、研究機関の強力なネットワークがヘルスケア・インフラを構成しています。このインフラは網膜生物学の創出、利用、研究を支援しています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場の概要

  • 主なハイライト

第3章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因
  • ポーターのファイブフォース分析

第4章 網膜生物製剤市場で展開される戦略

第5章 世界の網膜生物製剤市場:適応症別

  • 黄斑変性症の世界市場:地域別
  • 世界の糖尿病網膜症市場:地域別
  • 世界のその他の市場:地域別

第6章 世界の網膜生物製剤市場:薬剤クラス別

  • 世界のVEGF-Aアンタゴニスト市場:地域別
  • 世界のその他の市場:地域別

第7章 世界の網膜生物製剤市場:流通チャネル別

  • 世界の病院薬局市場:地域別
  • 世界の小売薬局市場:地域別
  • 世界のオンライン薬局市場:地域別

第8章 世界の網膜生物製剤市場:地域別

  • 北米
    • 北米の市場:国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場:国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場:国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場:国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第9章 企業プロファイル

  • Novartis AG
  • Amgen, Inc
  • AbbVie, Inc
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc
  • Santen Pharmaceutical Co, Ltd.
  • Bausch Health Companies, Inc
  • F Hoffmann-La Roche Ltd.
  • MeiraGTx Holdings plc
  • Oxurion NV

第10章 網膜生物製剤市場にとって勝利は必須

図表

LIST OF TABLES

  • TABLE 1 Global Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 2 Global Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 3 Global Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 4 Global Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 5 Global Macular Degeneration Market by Region, 2019 - 2022, USD Million
  • TABLE 6 Global Macular Degeneration Market by Region, 2023 - 2030, USD Million
  • TABLE 7 Global Diabetic Retinopathy Market by Region, 2019 - 2022, USD Million
  • TABLE 8 Global Diabetic Retinopathy Market by Region, 2023 - 2030, USD Million
  • TABLE 9 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 11 Global Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 12 Global Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 13 Global VEGF-A Antagonist Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global VEGF-A Antagonist Market by Region, 2023 - 2030, USD Million
  • TABLE 15 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 16 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 17 Global Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 18 Global Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 19 Global Hospital Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Hospital Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 21 Global Retail Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 22 Global Retail Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 23 Global Online Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Online Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 25 Global Retinal Biologics Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Retinal Biologics Market by Region, 2023 - 2030, USD Million
  • TABLE 27 North America Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 28 North America Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 29 North America Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 30 North America Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 31 North America Macular Degeneration Market by Country, 2019 - 2022, USD Million
  • TABLE 32 North America Macular Degeneration Market by Country, 2023 - 2030, USD Million
  • TABLE 33 North America Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
  • TABLE 34 North America Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
  • TABLE 35 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 36 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 37 North America Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 38 North America Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 39 North America VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
  • TABLE 41 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 43 North America Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 44 North America Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 45 North America Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 47 North America Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 49 North America Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 50 North America Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 51 North America Retinal Biologics Market by Country, 2019 - 2022, USD Million
  • TABLE 52 North America Retinal Biologics Market by Country, 2023 - 2030, USD Million
  • TABLE 53 US Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 54 US Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 55 US Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 56 US Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 57 US Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 58 US Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 59 US Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 60 US Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 61 Canada Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 62 Canada Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 63 Canada Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 64 Canada Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 65 Canada Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 66 Canada Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 67 Canada Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 68 Canada Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 69 Mexico Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 70 Mexico Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 71 Mexico Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 72 Mexico Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 73 Mexico Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 74 Mexico Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 75 Mexico Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 76 Mexico Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 77 Rest of North America Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 78 Rest of North America Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 79 Rest of North America Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 80 Rest of North America Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 81 Rest of North America Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 82 Rest of North America Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 83 Rest of North America Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 84 Rest of North America Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 85 Europe Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 86 Europe Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 87 Europe Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 88 Europe Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 89 Europe Macular Degeneration Market by Country, 2019 - 2022, USD Million
  • TABLE 90 Europe Macular Degeneration Market by Country, 2023 - 2030, USD Million
  • TABLE 91 Europe Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
  • TABLE 92 Europe Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
  • TABLE 93 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 94 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 95 Europe Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 96 Europe Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 97 Europe VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
  • TABLE 99 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 101 Europe Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 102 Europe Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 103 Europe Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 104 Europe Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 105 Europe Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 106 Europe Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 107 Europe Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 108 Europe Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 109 Europe Retinal Biologics Market by Country, 2019 - 2022, USD Million
  • TABLE 110 Europe Retinal Biologics Market by Country, 2023 - 2030, USD Million
  • TABLE 111 Germany Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 112 Germany Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 113 Germany Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 114 Germany Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 115 Germany Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 116 Germany Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 117 Germany Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 118 Germany Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 119 UK Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 120 UK Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 121 UK Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 122 UK Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 123 UK Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 124 UK Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 125 UK Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 126 UK Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 127 France Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 128 France Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 129 France Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 130 France Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 131 France Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 132 France Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 133 France Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 134 France Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 135 Russia Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 136 Russia Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 137 Russia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 138 Russia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 139 Russia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 140 Russia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 141 Russia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 142 Russia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 143 Spain Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 144 Spain Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 145 Spain Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 146 Spain Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 147 Spain Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 148 Spain Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 149 Spain Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 150 Spain Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 151 Italy Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 152 Italy Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 153 Italy Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 154 Italy Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 155 Italy Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 156 Italy Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 157 Italy Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 158 Italy Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 159 Rest of Europe Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 160 Rest of Europe Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 161 Rest of Europe Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 162 Rest of Europe Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 163 Rest of Europe Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 164 Rest of Europe Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 165 Rest of Europe Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 166 Rest of Europe Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 167 Asia Pacific Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 168 Asia Pacific Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 169 Asia Pacific Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 170 Asia Pacific Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 171 Asia Pacific Macular Degeneration Market by Country, 2019 - 2022, USD Million
  • TABLE 172 Asia Pacific Macular Degeneration Market by Country, 2023 - 2030, USD Million
  • TABLE 173 Asia Pacific Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
  • TABLE 174 Asia Pacific Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
  • TABLE 175 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 176 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 177 Asia Pacific Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 178 Asia Pacific Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 179 Asia Pacific VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
  • TABLE 180 Asia Pacific VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
  • TABLE 181 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 182 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 183 Asia Pacific Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 184 Asia Pacific Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 185 Asia Pacific Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Asia Pacific Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 187 Asia Pacific Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 188 Asia Pacific Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 189 Asia Pacific Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 190 Asia Pacific Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 191 Asia Pacific Retinal Biologics Market by Country, 2019 - 2022, USD Million
  • TABLE 192 Asia Pacific Retinal Biologics Market by Country, 2023 - 2030, USD Million
  • TABLE 193 China Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 194 China Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 195 China Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 196 China Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 197 China Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 198 China Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 199 China Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 200 China Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 201 Japan Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 202 Japan Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 203 Japan Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 204 Japan Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 205 Japan Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 206 Japan Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 207 Japan Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 208 Japan Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 209 India Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 210 India Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 211 India Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 212 India Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 213 India Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 214 India Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 215 India Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 216 India Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 217 South Korea Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 218 South Korea Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 219 South Korea Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 220 South Korea Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 221 South Korea Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 222 South Korea Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 223 South Korea Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 224 South Korea Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 225 Singapore Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 226 Singapore Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 227 Singapore Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 228 Singapore Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 229 Singapore Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 230 Singapore Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 231 Singapore Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 232 Singapore Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 233 Malaysia Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 234 Malaysia Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 235 Malaysia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 236 Malaysia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 237 Malaysia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 238 Malaysia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 239 Malaysia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 240 Malaysia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 241 Rest of Asia Pacific Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 242 Rest of Asia Pacific Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 243 Rest of Asia Pacific Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 244 Rest of Asia Pacific Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 245 Rest of Asia Pacific Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 246 Rest of Asia Pacific Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 247 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 248 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 249 LAMEA Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 250 LAMEA Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 251 LAMEA Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 252 LAMEA Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 253 LAMEA Macular Degeneration Market by Country, 2019 - 2022, USD Million
  • TABLE 254 LAMEA Macular Degeneration Market by Country, 2023 - 2030, USD Million
  • TABLE 255 LAMEA Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
  • TABLE 256 LAMEA Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
  • TABLE 257 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 258 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 259 LAMEA Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 260 LAMEA Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 261 LAMEA VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
  • TABLE 262 LAMEA VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
  • TABLE 263 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 264 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 265 LAMEA Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 266 LAMEA Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 267 LAMEA Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 268 LAMEA Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 269 LAMEA Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 270 LAMEA Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 271 LAMEA Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 272 LAMEA Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 273 LAMEA Retinal Biologics Market by Country, 2019 - 2022, USD Million
  • TABLE 274 LAMEA Retinal Biologics Market by Country, 2023 - 2030, USD Million
  • TABLE 275 Brazil Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 276 Brazil Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 277 Brazil Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 278 Brazil Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 279 Brazil Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 280 Brazil Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 281 Brazil Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 282 Brazil Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 283 Argentina Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 284 Argentina Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 285 Argentina Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 286 Argentina Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 287 Argentina Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 288 Argentina Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 289 Argentina Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 290 Argentina Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 291 UAE Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 292 UAE Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 293 UAE Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 294 UAE Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 295 UAE Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 296 UAE Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 297 UAE Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 298 UAE Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 299 Saudi Arabia Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 300 Saudi Arabia Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 301 Saudi Arabia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 302 Saudi Arabia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 303 Saudi Arabia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 304 Saudi Arabia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 305 Saudi Arabia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 306 Saudi Arabia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 307 South Africa Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 308 South Africa Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 309 South Africa Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 310 South Africa Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 311 South Africa Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 312 South Africa Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 313 South Africa Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 314 South Africa Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 315 Nigeria Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 316 Nigeria Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 317 Nigeria Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 318 Nigeria Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 319 Nigeria Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 320 Nigeria Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 321 Nigeria Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 322 Nigeria Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 323 Rest of LAMEA Retinal Biologics Market, 2019 - 2022, USD Million
  • TABLE 324 Rest of LAMEA Retinal Biologics Market, 2023 - 2030, USD Million
  • TABLE 325 Rest of LAMEA Retinal Biologics Market by Indication, 2019 - 2022, USD Million
  • TABLE 326 Rest of LAMEA Retinal Biologics Market by Indication, 2023 - 2030, USD Million
  • TABLE 327 Rest of LAMEA Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 328 Rest of LAMEA Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 329 Rest of LAMEA Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 330 Rest of LAMEA Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 331 Key Information - Novartis AG
  • TABLE 332 Key Information - Amgen, Inc.
  • TABLE 333 Key information - AbbVie, Inc.
  • TABLE 334 Key Information - Bayer AG
  • TABLE 335 Key Information - Regeneron Pharmaceuticals, Inc.
  • TABLE 336 Key Information - Santen Pharmaceutical Co., Ltd.
  • TABLE 337 key information - Bausch Health Companies, Inc.
  • TABLE 338 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
  • TABLE 339 Key Information - MeiraGTx Holdings plc
  • TABLE 340 Key Information - Oxurion NV

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Retinal Biologics Market, 2019 - 2030, USD Million
  • FIG 3 Key Factors Impacting Retinal Biologics Market
  • FIG 4 Porter's Five Forces Analysis - Retinal Biologics Market
  • FIG 5 Global Retinal Biologics Market share by Indication, 2022
  • FIG 6 Global Retinal Biologics Market share by Indication, 2030
  • FIG 7 Global Retinal Biologics Market by Indication, 2019 - 2030, USD Million
  • FIG 8 Global Retinal Biologics Market share by Drug Class, 2022
  • FIG 9 Global Retinal Biologics Market share by Drug Class, 2030
  • FIG 10 Global Retinal Biologics Market by Drug Class, 2019 - 2030, USD Million
  • FIG 11 Global Retinal Biologics Market share by Distribution Channel, 2022
  • FIG 12 Global Retinal Biologics Market share by Distribution Channel, 2030
  • FIG 13 Global Retinal Biologics Market by Distribution Channel, 2019 - 2030, USD Million
  • FIG 14 Global Retinal Biologics Market share by Region, 2022
  • FIG 15 Global Retinal Biologics Market share by Region, 2030
  • FIG 16 Global Retinal Biologics Market by Region, 2019 - 2030, USD Million
  • FIG 17 SWOT Analysis: Novartis AG
  • FIG 18 Swot Analysis: Amgen, Inc.
  • FIG 19 Swot Analysis: AbbVie, Inc.
  • FIG 20 Swot Analysis: Bayer AG
  • FIG 21 Swot Analysis: Regeneron Pharmaceuticals, Inc.
  • FIG 22 Swot Analysis: Santen Pharmaceutical Co., Ltd.
  • FIG 23 Recent strategies and developments: Bausch Health Companies, Inc.
  • FIG 24 Swot Analysis: Bausch Health Companies, Inc.
  • FIG 25 Swot Analysis: F. Hoffmann-La Roche Ltd.
  • FIG 26 Swot Analysis: MeiraGTx Holdings plc
  • FIG 27 Swot Analysis: Oxurion NV
目次

The Global Retinal Biologics Market size is expected to reach $20.7 billion by 2030, rising at a market growth of 5.4% CAGR during the forecast period.

As people age, a variety of diseases and issues can arise. The senior population is more at risk of the age-related progression of AMD disease thus, the macular degeneration segment will register around 60% share in the market by 2030. For example, By 2050, there will be about 1.5 billion people on the planet, a rise of more than three times the current population. Additionally, it is anticipated that by this time, 16.0% of people will be over the age of 60 worldwide. One out of every six people will be 65 or older by the middle of the twenty-first century. The global increase in the number and prevalence of older people is known as the "population aging phenomenon." In 2019, there were 703 million people worldwide who were 65 or older. People 65 and over made up 9% more of the population in 2019 than they did in 2018. Some of the factors impacting the market Technological advances aiding in the development of retinal biologics, Rising prevalence of retinal and eye issues, and longer time periods for drug approval.

Retinal biologic products have undergone technological breakthroughs that have improved their safety and effectiveness profiles, which has led to a rise in patient uptake across the globe. Significant R&D expenditures and business partnerships among market players are advantageous for developing retinal biology. The technical advances place a strong focus on research and development (R&D) pertaining to retinal gene treatments conducted by various institutes, biologics firms, and innovative product launches by key players in the form of implants and biologics. Additionally, Because of the increasing number of initiatives taken by various healthcare organizations, governmental entities, and industry actors, there is a greater awareness among the general public about ocular problems, which is leading to a higher diagnostic and treatment rate in the population. Concern regarding diabetic retinopathy has grown as more adults with type I and type II diabetes are losing their vision as a result of the disease. Thus, technological improvements in retinal biologics products and increasing prevalence of ocular issues will augment the expansion of the market in the coming years.

However, a number of pricey regulatory approvals and research phases are necessary for drug approval. The process of approving a medicine involves several phases of regulatory agency screening, including about four clinical trial steps. The costs of failing studies are high because clinical trial phases need large investments. For instance, according to a Forbes article, a medication producer invests approximately $350 million in each therapy before it is put on the market. Long wait times also cost these producers money, which hinders the expansion of the market. Furthermore, workflows in the healthcare industry were affected globally by the COVID-19 pandemic. Several areas of the healthcare sector, as well as several other industries, temporarily closed their doors due to the sickness. The COVID-19-led worldwide economic slowdown caused a drop in the market in 2020. The pandemic also caused supply chains in several end-user industries to fall, including the pharmaceutical, healthcare, and industrial sectors. This limited the market and impacted the release of innovative medicines.

Indication Outlook

Based on indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. The macular degeneration segment procured the highest revenue share in the market in 2022. Retinal biologics can help maintain eyesight and stop additional vision loss in people with macular degeneration by lowering inflammation in the retina and limiting the formation of aberrant blood vessels. Biologics used early and effectively can sometimes stabilize or even improve vision. The frequency of injections or treatments is decreased by some retinal biologics' extended-release formulations.

Drug Class Outlook

On the basis of drug class, the market is segmented into VEGF-A antagonist and others. The others segment recorded a significant revenue share in the market in 2022. The other segment mostly includes biologics developed from TNF-α. The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) is generated by macrophages and T-cells. It is significant in both inflammation and apoptosis. TNF-α is considered part of developing inflammatory, edematous, neovascular, and neurodegenerative illnesses in the eye.

Distribution Channel Outlook

Based on distribution channel, the market is divided into hospital pharmacy, online pharmacy, and retail pharmacy. The online pharmacy segment procured a considerable growth rate in the market in 2022. One of the key factors influencing the segment's growth is the increasing number of patients visiting ophthalmology clinics for the treatment of various eye conditions. In both established and developing nations, there are more and more people using the internet, and patients are increasingly choosing to buy their drugs online.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region recorded the largest revenue share in the market in 2022. The existence of numerous significant players, including Bayer AG, and Novartis AG, as well as developments in the production of retinal biologics, are driving the market's expansion. Additionally, easier access to retinal biologics medications and greater public awareness of the importance of early detection and treatment are key factors driving market expansion in this region. In addition, a strong network of hospitals, clinics, and research institutions makes up the healthcare infrastructure. This infrastructure aids in the creation, use, and study of retinal biology.

Strategies deployed in Retinal Biologics Market

Jul-2023: Bausch + Lomb acquired the Blink over-the-counter (OTC) line of eye drops from Johnson & Johnson Vision. The acquisition expanded the former company's portfolio of OTC eye care products and the addition would enable the company to provide enhanced convenience to consumers.

May-2023: Bausch + Lomb, the eyecare division of Bausch Health, received approval from the U.S. Food and Drug Administration for Miebo drops for dry eye disease. The medication fills a sizable gap in patient care as it is the only FDA-approved treatment to specifically target tear evaporation.

Feb-2023: AbbVie extended its collaboration with Capsida Biotherapeutics, a fully integrated next-generation gene therapy platform company, for developing genetic medicines for eye problems. Capsida's cutting-edge adeno-associated virus (AAV) engineering platform and manufacturing expertise will be integrated with AbbVie's comprehensive capabilities to identify and advance three candidates.

Aug-2022: Bausch + Lomb partnered with Munich Surgical Planning (MSI), a subsidiary of Heidelberg Engineering. To meet the rising demand for digital microscopy, this partnership aimed to bring together Bausch + Lomb's surgical expertise in the cataract, refractive, and vitreoretinal space with MSI's visualization and image guidance expertise, including an integrated high-speed SSOCT powered by Heidelberg Engineering.

Jul-2022: Roche came into partnership with Avista Therapeutics, a company focused on developing innovative gene therapies for retinal diseases, for developing novel AAV gene therapy vectors for eyes. The partnership aimed to use Avista's single-cell adeno-associated virus engineering (scAAVengr) platform technology to create intravitreal AAV capsids that fit a capsid profile specified by Roche. Moreover, Roche is in charge of conducting preclinical, clinical, and commercialization activities for gene therapy programs using these novel capsids, which is different from Avista's internal pipeline. Roche will also have the right to evaluate and license novel capsids from Avista.

Feb-2022: Roche received the U.S. Food and Drug Administration approval for Vabysmo (faricimab-svoa) for the treatment of neovascular Diabetic Macular Edema (DME) and Age-related Macular Degeneration (nAMD). Vabysmo neutralizes the disease-related proteins angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), which are associated with a range of retinal disorders that can impair vision.

Jan-2022: AbbVie got the U.S. Food and Drug Administration (FDA) approval for RINVOQ® (upadacitinib). This medication is indicated for the treatment of moderate to severe atopic dermatitis in children 12 years of age and above and adults.

Dec-2021: Novartis signed an agreement to acquire Gyroscope Therapeutics, a clinical-stage gene therapy company. Through this acquisition, Novartis would achieve access to the prior guide experimental gene treatment, GT005.

Mar-2021: Roche signed a collaboration and licensing agreement with SemaThera, a company focused on creating novel therapies for retinopathies. The partnership was focused on creating SemaThera's exciting new class of biologicals for the management of ischemic retinal disorders, such as diabetic retinopathy.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.

Scope of the Study

Market Segments covered in the Report:

By Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Others

By Drug Class

  • VEGF-A Antagonist
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • Amgen, Inc.
  • AbbVie, Inc.
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health Companies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • MeiraGTx Holdings plc
  • Oxurion NV

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Retinal Biologics Market, by Indication
    • 1.4.2 Global Retinal Biologics Market, by Drug Class
    • 1.4.3 Global Retinal Biologics Market, by Distribution Channel
    • 1.4.4 Global Retinal Biologics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
  • 3.3 Porter's Five Forces Analysis

Chapter 4. Strategies deployed in Retinal Biologics Market

Chapter 5. Global Retinal Biologics Market by Indication

  • 5.1 Global Macular Degeneration Market by Region
  • 5.2 Global Diabetic Retinopathy Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global Retinal Biologics Market by Drug Class

  • 6.1 Global VEGF-A Antagonist Market by Region
  • 6.2 Global Others Market by Region

Chapter 7. Global Retinal Biologics Market by Distribution Channel

  • 7.1 Global Hospital Pharmacy Market by Region
  • 7.2 Global Retail Pharmacy Market by Region
  • 7.3 Global Online Pharmacy Market by Region

Chapter 8. Global Retinal Biologics Market by Region

  • 8.1 North America Retinal Biologics Market
    • 8.1.1 North America Retinal Biologics Market by Indication
      • 8.1.1.1 North America Macular Degeneration Market by Country
      • 8.1.1.2 North America Diabetic Retinopathy Market by Country
      • 8.1.1.3 North America Others Market by Country
    • 8.1.2 North America Retinal Biologics Market by Drug Class
      • 8.1.2.1 North America VEGF-A Antagonist Market by Country
      • 8.1.2.2 North America Others Market by Country
    • 8.1.3 North America Retinal Biologics Market by Distribution Channel
      • 8.1.3.1 North America Hospital Pharmacy Market by Country
      • 8.1.3.2 North America Retail Pharmacy Market by Country
      • 8.1.3.3 North America Online Pharmacy Market by Country
    • 8.1.4 North America Retinal Biologics Market by Country
      • 8.1.4.1 US Retinal Biologics Market
        • 8.1.4.1.1 US Retinal Biologics Market by Indication
        • 8.1.4.1.2 US Retinal Biologics Market by Drug Class
        • 8.1.4.1.3 US Retinal Biologics Market by Distribution Channel
      • 8.1.4.2 Canada Retinal Biologics Market
        • 8.1.4.2.1 Canada Retinal Biologics Market by Indication
        • 8.1.4.2.2 Canada Retinal Biologics Market by Drug Class
        • 8.1.4.2.3 Canada Retinal Biologics Market by Distribution Channel
      • 8.1.4.3 Mexico Retinal Biologics Market
        • 8.1.4.3.1 Mexico Retinal Biologics Market by Indication
        • 8.1.4.3.2 Mexico Retinal Biologics Market by Drug Class
        • 8.1.4.3.3 Mexico Retinal Biologics Market by Distribution Channel
      • 8.1.4.4 Rest of North America Retinal Biologics Market
        • 8.1.4.4.1 Rest of North America Retinal Biologics Market by Indication
        • 8.1.4.4.2 Rest of North America Retinal Biologics Market by Drug Class
        • 8.1.4.4.3 Rest of North America Retinal Biologics Market by Distribution Channel
  • 8.2 Europe Retinal Biologics Market
    • 8.2.1 Europe Retinal Biologics Market by Indication
      • 8.2.1.1 Europe Macular Degeneration Market by Country
      • 8.2.1.2 Europe Diabetic Retinopathy Market by Country
      • 8.2.1.3 Europe Others Market by Country
    • 8.2.2 Europe Retinal Biologics Market by Drug Class
      • 8.2.2.1 Europe VEGF-A Antagonist Market by Country
      • 8.2.2.2 Europe Others Market by Country
    • 8.2.3 Europe Retinal Biologics Market by Distribution Channel
      • 8.2.3.1 Europe Hospital Pharmacy Market by Country
      • 8.2.3.2 Europe Retail Pharmacy Market by Country
      • 8.2.3.3 Europe Online Pharmacy Market by Country
    • 8.2.4 Europe Retinal Biologics Market by Country
      • 8.2.4.1 Germany Retinal Biologics Market
        • 8.2.4.1.1 Germany Retinal Biologics Market by Indication
        • 8.2.4.1.2 Germany Retinal Biologics Market by Drug Class
        • 8.2.4.1.3 Germany Retinal Biologics Market by Distribution Channel
      • 8.2.4.2 UK Retinal Biologics Market
        • 8.2.4.2.1 UK Retinal Biologics Market by Indication
        • 8.2.4.2.2 UK Retinal Biologics Market by Drug Class
        • 8.2.4.2.3 UK Retinal Biologics Market by Distribution Channel
      • 8.2.4.3 France Retinal Biologics Market
        • 8.2.4.3.1 France Retinal Biologics Market by Indication
        • 8.2.4.3.2 France Retinal Biologics Market by Drug Class
        • 8.2.4.3.3 France Retinal Biologics Market by Distribution Channel
      • 8.2.4.4 Russia Retinal Biologics Market
        • 8.2.4.4.1 Russia Retinal Biologics Market by Indication
        • 8.2.4.4.2 Russia Retinal Biologics Market by Drug Class
        • 8.2.4.4.3 Russia Retinal Biologics Market by Distribution Channel
      • 8.2.4.5 Spain Retinal Biologics Market
        • 8.2.4.5.1 Spain Retinal Biologics Market by Indication
        • 8.2.4.5.2 Spain Retinal Biologics Market by Drug Class
        • 8.2.4.5.3 Spain Retinal Biologics Market by Distribution Channel
      • 8.2.4.6 Italy Retinal Biologics Market
        • 8.2.4.6.1 Italy Retinal Biologics Market by Indication
        • 8.2.4.6.2 Italy Retinal Biologics Market by Drug Class
        • 8.2.4.6.3 Italy Retinal Biologics Market by Distribution Channel
      • 8.2.4.7 Rest of Europe Retinal Biologics Market
        • 8.2.4.7.1 Rest of Europe Retinal Biologics Market by Indication
        • 8.2.4.7.2 Rest of Europe Retinal Biologics Market by Drug Class
        • 8.2.4.7.3 Rest of Europe Retinal Biologics Market by Distribution Channel
  • 8.3 Asia Pacific Retinal Biologics Market
    • 8.3.1 Asia Pacific Retinal Biologics Market by Indication
      • 8.3.1.1 Asia Pacific Macular Degeneration Market by Country
      • 8.3.1.2 Asia Pacific Diabetic Retinopathy Market by Country
      • 8.3.1.3 Asia Pacific Others Market by Country
    • 8.3.2 Asia Pacific Retinal Biologics Market by Drug Class
      • 8.3.2.1 Asia Pacific VEGF-A Antagonist Market by Country
      • 8.3.2.2 Asia Pacific Others Market by Country
    • 8.3.3 Asia Pacific Retinal Biologics Market by Distribution Channel
      • 8.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
      • 8.3.3.2 Asia Pacific Retail Pharmacy Market by Country
      • 8.3.3.3 Asia Pacific Online Pharmacy Market by Country
    • 8.3.4 Asia Pacific Retinal Biologics Market by Country
      • 8.3.4.1 China Retinal Biologics Market
        • 8.3.4.1.1 China Retinal Biologics Market by Indication
        • 8.3.4.1.2 China Retinal Biologics Market by Drug Class
        • 8.3.4.1.3 China Retinal Biologics Market by Distribution Channel
      • 8.3.4.2 Japan Retinal Biologics Market
        • 8.3.4.2.1 Japan Retinal Biologics Market by Indication
        • 8.3.4.2.2 Japan Retinal Biologics Market by Drug Class
        • 8.3.4.2.3 Japan Retinal Biologics Market by Distribution Channel
      • 8.3.4.3 India Retinal Biologics Market
        • 8.3.4.3.1 India Retinal Biologics Market by Indication
        • 8.3.4.3.2 India Retinal Biologics Market by Drug Class
        • 8.3.4.3.3 India Retinal Biologics Market by Distribution Channel
      • 8.3.4.4 South Korea Retinal Biologics Market
        • 8.3.4.4.1 South Korea Retinal Biologics Market by Indication
        • 8.3.4.4.2 South Korea Retinal Biologics Market by Drug Class
        • 8.3.4.4.3 South Korea Retinal Biologics Market by Distribution Channel
      • 8.3.4.5 Singapore Retinal Biologics Market
        • 8.3.4.5.1 Singapore Retinal Biologics Market by Indication
        • 8.3.4.5.2 Singapore Retinal Biologics Market by Drug Class
        • 8.3.4.5.3 Singapore Retinal Biologics Market by Distribution Channel
      • 8.3.4.6 Malaysia Retinal Biologics Market
        • 8.3.4.6.1 Malaysia Retinal Biologics Market by Indication
        • 8.3.4.6.2 Malaysia Retinal Biologics Market by Drug Class
        • 8.3.4.6.3 Malaysia Retinal Biologics Market by Distribution Channel
      • 8.3.4.7 Rest of Asia Pacific Retinal Biologics Market
        • 8.3.4.7.1 Rest of Asia Pacific Retinal Biologics Market by Indication
        • 8.3.4.7.2 Rest of Asia Pacific Retinal Biologics Market by Drug Class
        • 8.3.4.7.3 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel
  • 8.4 LAMEA Retinal Biologics Market
    • 8.4.1 LAMEA Retinal Biologics Market by Indication
      • 8.4.1.1 LAMEA Macular Degeneration Market by Country
      • 8.4.1.2 LAMEA Diabetic Retinopathy Market by Country
      • 8.4.1.3 LAMEA Others Market by Country
    • 8.4.2 LAMEA Retinal Biologics Market by Drug Class
      • 8.4.2.1 LAMEA VEGF-A Antagonist Market by Country
      • 8.4.2.2 LAMEA Others Market by Country
    • 8.4.3 LAMEA Retinal Biologics Market by Distribution Channel
      • 8.4.3.1 LAMEA Hospital Pharmacy Market by Country
      • 8.4.3.2 LAMEA Retail Pharmacy Market by Country
      • 8.4.3.3 LAMEA Online Pharmacy Market by Country
    • 8.4.4 LAMEA Retinal Biologics Market by Country
      • 8.4.4.1 Brazil Retinal Biologics Market
        • 8.4.4.1.1 Brazil Retinal Biologics Market by Indication
        • 8.4.4.1.2 Brazil Retinal Biologics Market by Drug Class
        • 8.4.4.1.3 Brazil Retinal Biologics Market by Distribution Channel
      • 8.4.4.2 Argentina Retinal Biologics Market
        • 8.4.4.2.1 Argentina Retinal Biologics Market by Indication
        • 8.4.4.2.2 Argentina Retinal Biologics Market by Drug Class
        • 8.4.4.2.3 Argentina Retinal Biologics Market by Distribution Channel
      • 8.4.4.3 UAE Retinal Biologics Market
        • 8.4.4.3.1 UAE Retinal Biologics Market by Indication
        • 8.4.4.3.2 UAE Retinal Biologics Market by Drug Class
        • 8.4.4.3.3 UAE Retinal Biologics Market by Distribution Channel
      • 8.4.4.4 Saudi Arabia Retinal Biologics Market
        • 8.4.4.4.1 Saudi Arabia Retinal Biologics Market by Indication
        • 8.4.4.4.2 Saudi Arabia Retinal Biologics Market by Drug Class
        • 8.4.4.4.3 Saudi Arabia Retinal Biologics Market by Distribution Channel
      • 8.4.4.5 South Africa Retinal Biologics Market
        • 8.4.4.5.1 South Africa Retinal Biologics Market by Indication
        • 8.4.4.5.2 South Africa Retinal Biologics Market by Drug Class
        • 8.4.4.5.3 South Africa Retinal Biologics Market by Distribution Channel
      • 8.4.4.6 Nigeria Retinal Biologics Market
        • 8.4.4.6.1 Nigeria Retinal Biologics Market by Indication
        • 8.4.4.6.2 Nigeria Retinal Biologics Market by Drug Class
        • 8.4.4.6.3 Nigeria Retinal Biologics Market by Distribution Channel
      • 8.4.4.7 Rest of LAMEA Retinal Biologics Market
        • 8.4.4.7.1 Rest of LAMEA Retinal Biologics Market by Indication
        • 8.4.4.7.2 Rest of LAMEA Retinal Biologics Market by Drug Class
        • 8.4.4.7.3 Rest of LAMEA Retinal Biologics Market by Distribution Channel

Chapter 9. Company Profiles

  • 9.1 Novartis AG
    • 9.1.1 Company Overview
    • 9.1.2 Financial Analysis
    • 9.1.3 Segmental and Regional Analysis
    • 9.1.4 Research & Development Expense
    • 9.1.5 Recent strategies and developments:
      • 9.1.5.1 Acquisition and Mergers:
    • 9.1.6 SWOT Analysis
  • 9.2 Amgen, Inc.
    • 9.2.1 Company Overview
    • 9.2.2 Financial Analysis
    • 9.2.3 Regional Analysis
    • 9.2.4 Research & Development Expenses
    • 9.2.5 SWOT Analysis
  • 9.3 AbbVie, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Analysis
    • 9.3.3 Regional Analysis
    • 9.3.4 Research & Development Expense
    • 9.3.5 Recent strategies and developments:
      • 9.3.5.1 Partnerships, Collaborations, and Agreements:
      • 9.3.5.2 Approvals & Trials:
    • 9.3.6 SWOT Analysis
  • 9.4 Bayer AG
    • 9.4.1 Company Overview
    • 9.4.2 Financial Analysis
    • 9.4.3 Segmental and Regional Analysis
    • 9.4.4 Research & Development Expense
    • 9.4.5 SWOT Analysis
  • 9.5 Regeneron Pharmaceuticals, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Financial Analysis
    • 9.5.3 Research & Development Expense
    • 9.5.4 SWOT Analysis
  • 9.6 Santen Pharmaceutical Co., Ltd.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Analysis
    • 9.6.3 Regional Analysis
    • 9.6.4 Research & Development Expenses
    • 9.6.5 SWOT Analysis
  • 9.7 Bausch Health Companies, Inc.
    • 9.7.1 Company Overview
    • 9.7.2 Financial Analysis
    • 9.7.3 Segmental and Regional Analysis
    • 9.7.4 Research & Development Expense
    • 9.7.5 Recent strategies and developments:
      • 9.7.5.1 Partnerships, Collaborations, and Agreements:
      • 9.7.5.2 Approvals & Trials:
      • 9.7.5.3 Acquisition and Mergers:
    • 9.7.6 SWOT Analysis
  • 9.8 F. Hoffmann-La Roche Ltd.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Analysis
    • 9.8.3 Segmental and Regional Analysis
    • 9.8.4 Research & Development Expense
    • 9.8.5 Recent strategies and developments:
      • 9.8.5.1 Partnerships, Collaborations, and Agreements:
      • 9.8.5.2 Approvals & Trials:
    • 9.8.6 SWOT Analysis
  • 9.9 MeiraGTx Holdings plc
    • 9.9.1 Company Overview
    • 9.9.2 Financial Analysis
    • 9.9.3 Research & Development Expenses
    • 9.9.4 SWOT Analysis
  • 9.10. Oxurion NV
    • 9.10.1 Company Overview
    • 9.10.2 Financial Analysis
    • 9.10.3 Research & Development Expenses
    • 9.10.4 SWOT Analysis

Chapter 10. Winning Imperative for Retinal Biologics Market